4D Path to Present New Data Demonstrating Enhanced Prediction of Chemotherapy Response in BRCA-Mutated and HER2-Negative Breast Cancer at ASCO 2025
Study highlights the potential of 4D Path’s QPOR™ platform to improve predictive accuracy for neoadjuvant chemotherapy response in patients with low stromal tumor-infiltrating lymphocytes…